PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction

Csaba Matyas,Eszter Trojnar,Suxian Zhao,Muhammad Arif,Partha Mukhopadhyay,Attila Kovacs,Alexandra Fabian,Marton Tokodi,Zsolt Bagyura,Bela Merkely,Laszlo Kohidai,Eszter Lajko,Angela Takacs,Yong He,Bin Gao,Janos Paloczi,Falk W. Lohoff,György Haskó,Wen-Xing Ding,Pal Pacher
DOI: https://doi.org/10.1016/j.jacbts.2023.06.005
IF: 9.531
2023-09-15
JACC Basic to Translational Science
Abstract:Summary Cardiovascular diseases (CVDs) are the leading cause of death among elderly people. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of cholesterol metabolism. Herein, we investigated the role of PCSK9 in age-related CVD. Both in humans and rats, blood PCSK9 level correlated positively with increasing age and the development of cardiovascular dysfunction. Age-related fatty degeneration of liver tissue positively correlated with serum PCSK9 levels in the rat model, while development of age-related nonalcoholic fatty liver disease correlated with cardiovascular functional impairment. Network analysis identified PCSK9 as an important factor in age-associated lipid alterations and it correlated positively with intima-media thickness, a clinical parameter of CVD risk. PCSK9 inhibition with alirocumab effectively reduced the CVD progression in aging rats, suggesting that PCSK9 plays an important role in cardiovascular aging.
cardiac & cardiovascular systems
What problem does this paper attempt to address?